Article
Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
Oncotarget - 20 Apr 2015
Park Angela K J, Francis Joshua M, Park Woong-Yang, Park Joon-Oh, Cho Jeonghee
Abstract excerpt
Genomic alterations targeting the Epidermal Growth Factor Receptor (EGFR) gene have been strongly associated with cancer pathogenesis. The clinical effectiveness of EGFR targeted therapies, including small molecules directed against the kinase domain such as gefitinib, erlotinib and afatinib, hav...
Topics
- Animals
- Antineoplastic Agents
- Enzyme Activation
- ErbB Receptors
- Exons
- Genes, erbB-1
- Heterografts
- Humans
- Inhibitory Concentration 50
- Mice
- Mice, Nude
- Molecular Targeted Therapy
- Mutation
- NIH 3T3 Cells
- Neoplasm Proteins
- Neoplasms, Experimental
- Phosphorylation
- Protein Kinase Inhibitors